592 related articles for article (PubMed ID: 9400001)
21. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor.
Gazi L; Bobirnac I; Danzeisen M; Schüpbach E; Bruinvels AT; Geisse S; Sommer B; Hoyer D; Tricklebank M; Schoeffter P
Br J Pharmacol; 1998 Jul; 124(5):889-96. PubMed ID: 9692773
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
[TBL] [Abstract][Full Text] [Related]
23. Combined alpha 2-adrenergic/D2 dopamine receptor blockade fails to reproduce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle.
Ballmaier M; Zoli M; Mazzoncini R; Gennarelli M; Spano F
Psychopharmacology (Berl); 2001 Dec; 159(1):105-10. PubMed ID: 11797077
[TBL] [Abstract][Full Text] [Related]
24. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat.
Stanhope KJ; Mirza NR; Bickerdike MJ; Bright JL; Harrington NR; Hesselink MB; Kennett GA; Lightowler S; Sheardown MJ; Syed R; Upton RL; Wadsworth G; Weiss SM; Wyatt A
J Pharmacol Exp Ther; 2001 Nov; 299(2):782-92. PubMed ID: 11602695
[TBL] [Abstract][Full Text] [Related]
25. 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor.
Kulagowski JJ; Broughton HB; Curtis NR; Mawer IM; Ridgill MP; Baker R; Emms F; Freedman SB; Marwood R; Patel S; Patel S; Ragan CI; Leeson PD
J Med Chem; 1996 May; 39(10):1941-2. PubMed ID: 8642550
[No Abstract] [Full Text] [Related]
26. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
Millan MJ; Loiseau F; Dekeyne A; Gobert A; Flik G; Cremers TI; Rivet JM; Sicard D; Billiras R; Brocco M
J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
[TBL] [Abstract][Full Text] [Related]
27. Effects of dopamine D4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions.
Zhang K; Davids E; Tarazi FI; Baldessarini RJ
Psychopharmacology (Berl); 2002 Apr; 161(1):100-6. PubMed ID: 11967637
[TBL] [Abstract][Full Text] [Related]
28. Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors.
Depoortère R; Bardin L; Rodrigues M; Abrial E; Aliaga M; Newman-Tancredi A
Behav Pharmacol; 2009 Jul; 20(4):303-11. PubMed ID: 19584712
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).
Okuyama S; Chaki S; Yoshikawa R; Suzuki Y; Ogawa S; Imagawa Y; Kawashima N; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539
[TBL] [Abstract][Full Text] [Related]
30. PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties.
Tang AH; Franklin SR; Himes CS; Smith MW; Tenbrink RE
J Pharmacol Exp Ther; 1997 Apr; 281(1):440-7. PubMed ID: 9103528
[TBL] [Abstract][Full Text] [Related]
31. 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.
Nakane M; Cowart MD; Hsieh GC; Miller L; Uchic ME; Chang R; Terranova MA; Donnelly-Roberts DL; Namovic MT; Miller TR; Wetter JM; Marsh K; Stewart AO; Brioni JD; Moreland RB
Neuropharmacology; 2005 Jul; 49(1):112-21. PubMed ID: 15992586
[TBL] [Abstract][Full Text] [Related]
32. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
Brocco M; Dekeyne A; Papp M; Millan MJ
Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
[TBL] [Abstract][Full Text] [Related]
34. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
[TBL] [Abstract][Full Text] [Related]
35. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.
Campiani G; Nacci V; Bechelli S; Ciani SM; Garofalo A; Fiorini I; Wikström H; de Boer P; Liao Y; Tepper PG; Cagnotto A; Mennini T
J Med Chem; 1998 Sep; 41(20):3763-72. PubMed ID: 9748351
[TBL] [Abstract][Full Text] [Related]
36. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
[TBL] [Abstract][Full Text] [Related]
37. Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice.
Xu R; Hranilovic D; Fetsko LA; Bucan M; Wang Y
Mol Psychiatry; 2002; 7(10):1075-82. PubMed ID: 12476322
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomers.
Meltzer LT; Caprathe BW; Christoffersen CL; Corbin AE; Jaen JC; Ninteman FW; Pugsley TA; Serpa KA; Shih YH; Whetzel SZ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1177-89. PubMed ID: 8103791
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
[TBL] [Abstract][Full Text] [Related]
40. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T
J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
